Savara is transitioning from a single-asset biotech to a rare disease commercial infrastructure, with MOLBREEVI targeting autoimmune PAP. SVRA's cash runway extends into H2 2027, bolstered by $203M in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results